BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
UNLOXCYT (cosibelimab) by Checkpoint Surgical is programmed death ligand-1 antagonists [moa]. Approved for b-cell non-hodgkin lymphoma, richter transformation. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Worked on UNLOXCYT at Checkpoint Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.